Skip to main content
Anil K Chauhan on Muck Rack

Anil K Chauhan

As seen in: Medium, Nature, BMJ Open, Frontiers, The Hindu, India Today, Royal Society of Chemistry, The Lancet, Neurology Journal, The Journal of Immunology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anil K

Contact Anil K, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cascade [3+2] Nitrone–Olefin Cycloaddition and Molybdenum-Mediated Oxidative Cyclization for Polycyclic Isoxazolidines and Tetrahydropyridines Click to copy article link Article link copied!

|
By Akhilesh Yadav, Anil K Chauhan, Raj Patel
| dx.doi.org
Open in Who Shared Issue with article?

Who is Anil Chauhan? Biography, Career and Profile

|
By Anil K Chauhan
| TechObserver.in Verified
Sourcing: Description: From Tech Observer archive — India outlines quantum technology strategy for Army, Navy and Air Force (2026-01-23). https://techobserver.in/news/egov/india-outlines-quantum-technology-strategy-for-army-navy-and-air-force-320178/ Pending editorial verification.
Open in Who Shared Issue with article?

Methods for randomized, blinded, controlled evaluation of putative disease interventions in multilaboratory, preclinical assessment networks - Lab Animal

|
By Jessica Lamb, Karisma Nagarkatti, Márcio Diniz, Ryan P Cabeen, Monica V. Estrada, Mónica Valeria Estrada, Karen Crawford, André Rogatko, Sungjin Kim, Cenk Ayata, David C Hess, Mohammad Khan, Rakesh Patel, Mariia Kumskova, Enrique C. Leira, Anil K Chauhan, Patrick D. Lyden
| Nature Verified
Abstract Science faces a reproducibility crisis, and public trust in science declines when large clinical trials, which had been qualified by promising preclinical studies, fail. While some clinical trial designs may have been inadequate, preclinical assessments of disease interventions might have lacked key elements of rigor such as treatment concealment, randomization, blinded outcomes, prespecified and adequate sample sizes, and models including comorbidities.
Open in Who Shared Issue with article?
See all 23 licensed articles (25 Total)